HIV/AIDSOptimal Management of HIV Therapies
spacer
mainmenu
programmenu
navfill
medslogo
navfill
sponsors 		spacer
Suggested Reading List

Department of Health and Human Services (DHHS). Antiretroviral Treatment Guidelines (4/7/2005). Available at: www.aidsinfo.nih.gov. Accessed October 8, 2005.

Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinial Trials Group. Clin Infect Dis. 2003 Sep 1;37(5):613-27.

Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004 Jul 23;18(11):1529-37.

Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005 Jun 1;40(11):1559-85.

Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000 Jan 12;283(2):229-34.

Holder DJ, Condra JH, Schleif WA, et al. Virologic Failure During Combination Therapy with CRIXIVAN and RT Inhibitors Is Often Associated with Expression of Resistance-Associated Mutations in RT Only. In: 6th Conference on Retroviruses and Opportunistic Infections (CROI). 1999 Jan. 31-Feb. 4. Chicago. Abstract 492.

Johnson VA, Brun-Vézinet F, Clotet B, et. al., Update of the Drug Resistance Mutations in HIV-1: 2005.Top HIV Med. 2005 Mar-Apr;13(1):51-7. Review.

Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. 2005 February 22-25. Boston. Abstract 164LB.

Kempf D, King M, Bauer E, et al. Comparative Incidence and Temporal Accumulation of PI and NRTI Resistance in HIV-infected Subjects Receiving Lopinavir/Ritonavir or Nelfinavir as Initial Therapy. 10th Conference on Retroviruses and Opportunistic Infections (CROI). 2003 Feb 10-14; Boston. Abstract 600.

Kurtizkes DR. Preventing and Managing Resistance in the Clinical Setting. J Acquir Immune Defic Syndr. 2003 Oct 1;34(suppl 2):S103-10.

Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004 Apr 30;18(7):1029-36.

McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004 Jan 15;38(2):263-70.

Melby T, Tortell S, Thorborn D, et al., Time to Appearance of NRTI-Associated Mutations and Response to Subsequent Therapy for Patients on Failing ABC/COM. In: 8th Conference on Retroviruses and Opportunistic Infections (CROI). 2001 Feb 4-8; Chicago. Abstract 448.

Nadler J, Rodriguez-French A, Millard J, et al. The NEAT study: GW433908 efficacy and safety in ART-naïve subjects, final 48-week Analysis. In: 10th Conference on Retroviruses and Opportunistic Infections (CROI). 2003 Feb 10-14; Boston. Abstract 177.

Negredo E, Bonjoch A, Paredes R, et al. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. Clin Infect Dis. 2005 Sep 15;41(6):901-5.

Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naïve patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005 Feb 1;40(3):468-74.

Novak RM, Chen L, MacArthur RD, et al. Prevalence of resistance mutations in a cohort of treatment-naïve people with chronic HIV infection in the U.S.: CPCRA 058. In: 15th International AIDS Conference (IAC).2004 Jul. 11-16. Bangkok, Thailand. Abstract WePeB5707.

Palella F, Deloria-Knoll M, Chmiel JS, et al., Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003 Apr 15;138(8):620-6.

Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):22-32.

Rusconi S, De Pasquale MP, Milazzo L, et al. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure. Antivir Ther. 1998;3(4):203-7.

Vavro C, McCarty D, Shortino D, et al., Genotypic Analysis of HIV-1 from Subjects Experiencing Virologic Breakthrough while taking 3TC QD vs 3TC BID, EFV and ZDV. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 2002 Sept. 27-30. San Diego. Abstract H-2052.

Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004 Jul 14;292(2):251-65.

arrow  Program Menu